Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2024 16:30 ET | Source: Surrozen, Inc.

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen to Present at Upcoming Healthcare Investor Conferences in November 2024
November 06, 2024 09:00 ET | Source: Surrozen, Inc.

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen Provides Third Quarter 2024 Financial Results and Business Update
November 04, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FIbrosis
September 24, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
August 12, 2024 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Provides Second Quarter 2024 Financial Results and Business Update
June 12, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Publishes Study in eLife Demonstrating the Promise of the SWEETS Platform, a Unique TPD Technology, to Further Enhance Wnt Signaling
June 10, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 at the 2024 European Association for the Study of the Liver (EASL) in Milan
June 04, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
May 09, 2024 08:30 ET | Source: Surrozen, Inc.

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
May 08, 2024 16:05 ET | Source: Surrozen, Inc.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Provides First Quarter 2024 Financial Results and Business Update